Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers
Jian Guan, Khin Sandar Lim, Tarek Mekhail, et al.
Archives of Pathology & Laboratory Medicine (2017) Vol. 141, Iss. 6, pp. 851-861
Open Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Weiting Qin, Li-Peng Hu, Xueli Zhang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 327
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
Dong Ha Kim, HyeongRyul Kim, Yun Jung Choi, et al.
Experimental & Molecular Medicine (2019) Vol. 51, Iss. 8, pp. 1-13
Open Access | Times Cited: 313
Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
Liisa Chang, Minna Chang, Hanna M. Chang, et al.
Applied immunohistochemistry & molecular morphology (2017) Vol. 26, Iss. 2, pp. e15-e21
Closed Access | Times Cited: 311
Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 96
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
Ying‐Nai Wang, Heng‐Huan Lee, Jennifer L. Hsu, et al.
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 135
FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
Aleksandra Sochacka-Ćwikła, Marcin Mą̨czyński, Andrzej Regiec
Cancers (2021) Vol. 14, Iss. 1, pp. 87-87
Open Access | Times Cited: 68
The role of AI technology in prediction, diagnosis and treatment of colorectal cancer
Chaoran Yu, Ernest Johann Helwig
Artificial Intelligence Review (2021) Vol. 55, Iss. 1, pp. 323-343
Open Access | Times Cited: 65
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation
Liang Deng, Guoqing Qian, Shuo Zhang, et al.
Oncogene (2019) Vol. 38, Iss. 35, pp. 6270-6282
Closed Access | Times Cited: 69
Preparation of Novel Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides and Their Experimental and Computational Biological Studies
Mateusz Kciuk, Somdutt Mujwar, Anna Szymanowska, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 5892-5892
Open Access | Times Cited: 30
PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis
Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3911-3911
Open Access | Times Cited: 28
Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method
Hocheol Lim, Jung-Ho Chun, Xuemei Jin, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 52
Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)
Carol C. Cheung, Penny J. Barnes, Gilbert Bigras, et al.
Applied immunohistochemistry & molecular morphology (2019) Vol. 27, Iss. 10, pp. 699-714
Open Access | Times Cited: 48
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi‐Yong Sun
Frontiers of Medicine (2020) Vol. 15, Iss. 2, pp. 221-231
Open Access | Times Cited: 45
Interferon‑γ induced PD‑L1 expression and soluble PD‑L1 production in gastric cancer
Yushi Imai, Tetsuhiro Chiba, Takayuki Kondo, et al.
Oncology Letters (2020) Vol. 20, Iss. 3, pp. 2161-2168
Open Access | Times Cited: 39
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
C. Faivre‐Finn, David R. Spigel, Suresh Senan, et al.
Lung Cancer (2020) Vol. 151, pp. 30-38
Open Access | Times Cited: 39
Adaptive Immunity Determines the Cancer Treatment Outcome of Oncolytic Virus and Anti-PD-1
Kang‐Ling Liao, Kenton D. Watt
Bulletin of Mathematical Biology (2025) Vol. 87, Iss. 3
Closed Access
Evaluating the efficacy and safety of immune checkpoint inhibitors in first and second-line treatments for recurrent and metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis of RCTs with a focus on PD-L1 expression
Wei Chen, Qichun Wei, Tong Xiao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
Samaneh Moradi, Pedram Sarikhani, Rafid Jihad Albadr, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Epigenetic regulators of programmed death-ligand 1 expression in human cancers
Sachin Kumar, Surender K. Sharawat
Translational research (2018) Vol. 202, pp. 129-145
Closed Access | Times Cited: 45
Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients
Atsushi Mitsuhashi, Yusuke Okuma
Clinical & Translational Oncology (2018) Vol. 20, Iss. 8, pp. 966-974
Closed Access | Times Cited: 44
Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer
Ashley K. Volaric, Ryan D. Gentzler, Richard D. Hall, et al.
The American Journal of Surgical Pathology (2018) Vol. 42, Iss. 9, pp. 1216-1223
Closed Access | Times Cited: 39
PD-1/PD-L1 in cardiovascular disease
Yunfeng Sun, Liang Li, Yawei Wu, et al.
Clinica Chimica Acta (2020) Vol. 505, pp. 26-30
Closed Access | Times Cited: 35
CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
Xin Li, Ling Chen, Chuan Gu, et al.
PeerJ (2020) Vol. 8, pp. e9536-e9536
Open Access | Times Cited: 34
Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity
Zuodong Ye, Yiding Xiong, Peng Wang, et al.
Advanced Science (2022) Vol. 10, Iss. 6
Open Access | Times Cited: 20
Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis
Hanlin Fu, Zhihui Fu, Meng Mao, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 189, pp. 104084-104084
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top